Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer

详细信息    查看全文

• 作者：Hongying Lv (1)
  Ting Han (1)
  Xiaoli Shi (1)
  Yasai Yao (1)
  Yongru Yao (2)
  Wensheng Qiu (1)
  Lu Yue (1)
  Jun Liang (1)
  
• 关键词：Non ; small cell lung cancer ; Gene polymorphism ; GSTP1 ; ERCC1 ; Platinum ; based chemotherapy ; Prognosis
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：31
• 期：8
• 全文大小：316 KB
• 参考文献：1. American Cancer Society. Cancer facts and figures?2013. Atlanta, Ga, USA: American Cancer Society; 2013. lus-plus">http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
  2. American Cancer Society. Non-small cell lung cancer; 2013. lungcancer-non-smallcell/index" class="a-plus-plus">http://www.cancer.org/cancer/lungcancer-non-smallcell/index.
  3. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-7. CrossRef
  4. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16:1745-5. CrossRef
  5. Xu J, Yin Z, Shen H, et al. A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One. 2013;8:e79135. CrossRef
  6. Okano Y, Nezu U, Enokida Y, et al. SNP (-17C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women. PLoS One. 2013;8:e73794. CrossRef
  7. Ding C, Li C, Wang H, Li B, Guo Z. A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer. Onco Targets Ther. 2013;6:877.
  8. Shitara M, Sasaki H, Yokota K, et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med. 2012;4:785-.
  9. Jung M, Cho BC, Lee CH, et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012;53:1128-5. CrossRef
  10. Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y. The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest. 2006;24:497-01. CrossRef
  11. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008;7:3247-5. CrossRef
  12. Medeiros R, Vasconcelos A, Costa S, et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate. 2004;58:414-0. CrossRef
  13. Sekine I, Minna JD, Nishio K, Tamura T, Saijo N. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol. 2006;1:31-. CrossRef
  14. Breen D, Barlési F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33:805-1. CrossRef
  15. Zhu C-Q, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010;28:4417-4. CrossRef
  16. London SJ, Yuan J-M, Chung F-L, et al. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet. 2000;356:724-. CrossRef
  17. Curran JE, Weinstein SR, Griffiths LR. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett. 2000;153:113-0. CrossRef
  18. Howells R, Holland T, Dhar K, et al. Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer. 2001;11:107-2. CrossRef
  19. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger J-M, Fargeot P, Brunet-Lecomte P. Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res. 1999;1:81. CrossRef
  20. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA. 2001;98:11592-. CrossRef
  21. Ada A, Hancer F, Bilgen S, et al. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma. 2010;57:512. CrossRef
  22. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118-3. CrossRef
  23. Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65:437-6. CrossRef
  24. Xu C, Feng D, Li L, et al. The expression and prognostic significance of ERCC1 and GST-pi in lung cancer. Chin J Lung Cancer. 2010;13(3):195-00.
  25. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Age. 2011;60:75.
  26. Li X-D, Han J-C, Zhang Y-J, Li H-B, Wu X-Y. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev. 2013;14:145-. CrossRef
  27. Tepeli E, Caner V, Büyükp?narba??l? N, et al. Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep. 2012;39:335-1. CrossRef
  28. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-. CrossRef
  29. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-1. CrossRef
  30. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286-1.
  31. Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2011;12:393-01. CrossRef
  32. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747-4. CrossRef
  33. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. CHEST J. 2005;127:978-3. CrossRef
  34. Choi C, Yang S, Jo H, et al. Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol. 2012;23:2088-3. CrossRef
  35. Seyhan EC, Alt?n S, ?etinkaya E, et al. Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg. 2011;17:110-. CrossRef
  36. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-1. CrossRef
  37. Tseden-Ish M, Choi YD, Cho HJ, et al. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Respirology. 2012;17:127-3. CrossRef
  38. Lee K-H, Min HS, Han S-W, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60:401-. lungcan.2007.10.014" target="_blank" title="It opens in new window">CrossRef
  39. Vilmar AC, Santoni-Rugiu E, S?rensen J. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21:1817-4. CrossRef
  40. Wang X, Zhao J, Yang L, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2010;27:484-0. CrossRef
  41. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non–small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254-. CrossRef
  42. Hubner RA, Riley RD, Billingham LJ, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One. 2011;6:e25164. CrossRef
  43. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010;70:63-0. lungcan.2010.05.010" target="_blank" title="It opens in new window">CrossRef
  44. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non–small-cell lung cancer. J Clin Oncol. 2009;27:5808-5. CrossRef
  45. Zhang S, Li Q, Zhang Q. Expression of ERCC1 and class III β-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy. Int J Biol Markers. 2010;25:141-.
  46. Bepler G, Olaussen KA, Vataire A-L, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011;178:69-8. CrossRef
  47. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902-. CrossRef
  48. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64:98-04. lungcan.2008.07.014" target="_blank" title="It opens in new window">CrossRef
  49. Friboulet L, Olaussen KA, Pignon J-P, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101-0. CrossRef
  50. Vollebergh MA, Kappers I, Klomp HM, et al. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1939-8. CrossRef
  51. Zalcman G, Levallet G, Bergot E, et al. Evaluation of class III beta-tubulin (bTubIII) expression as a prognostic marker in patients with resectable non-small cell lung cancer (NSCLC) treated by perioperative chemotherapy (CT) in the phase III trial IFCT-0002. J Clin Oncol. 2009;27:7526.
  52. Herbst R, Blumenschein G Jr, Kim E, et al. Sorafenib treatment efficacy and KRAS biomarker status in the biomarker-integrated approaches of targeted therapy for lung cancer elimination (BATTLE) trial. J Clin Oncol. 2010;28:7609.
  53. Shepherd FA, Tsao M-S. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol. 2010;28:903-. CrossRef
  
• 作者单位：Hongying Lv (1)
  Ting Han (1)
  Xiaoli Shi (1)
  Yasai Yao (1)
  Yongru Yao (2)
  Wensheng Qiu (1)
  Lu Yue (1)
  Jun Liang (1)
  
  1. Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
  2. Department of Central Experiment, Affiliated Hospital of Qingdao University, Qingdao, 266003, People’s Republic of China
  
• ISSN：1559-131X

文摘

The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Ninety-one patients with metastatic non-small lung cancer were evaluated. Blood samples were obtained from each patient before chemotherapy. They are all administered modified TP, GP, NP regimens. Curative effects in patients were evaluated after at least two cycles of treatment. TTP was calculated. The response rate of GSTP1 with G/G?+?G/A group and A/A group is 54.55?% (24/44) and 21.28?% (10/47) (P?=?0.001), respectively. The response rate of ERCC1 with C/C group and C/T?+?T/T group is 51.11?% (23/45) and 23.91?% (11/46) (P?=?0.007), respectively. Patients with both G/G?+?G/A and C/C has the response rate of 64.52?% (20/31) (P?=?0.000). Logistic regression analysis shows a significant increased chance of treatment response in patients with G/G?+?G/A genotype versus A/A genotype (P?=?0.008) and with T/T?+?C/T genotype versus C/C genotype (P?=?0.001). The median TTP of all patients is 7.32?months. The TTP of individuals with G/G?+?G/A genotype is 9.56?months, and those with A/A genotype had an TTP of 5.23?months. The TTP of individuals with C/C genotype is 9.16?months, and those with T/T?+?C/T genotype is 5.53?months. Kaplan–Meier analysis shows that ERCC1 and GSTP1 polymorphisms are correlated with TTP. The log-rank test is was marginally significant (P?